#United States #New York #Securities Fraud #Rosen Law Firm #Unicycive

Class Action Opportunity for Unicycive Therapeutics Investors

Unicycive Therapeutics, a company listed on NASDAQ under the symbol UNCY, is currently at the center of a potential class action lawsuit concerning securities fraud. As announced by the Rosen Law Firm—a global legal entity dedicated to investor rights—individuals who purchased Unicycive securities from December 29, 2025, to June 29, 2026, have until November 2, 2026, to take action as lead plaintiffs in this case.

Important Deadlines for Investors

Investors who bought Unicycive's stock during the defined class period should be aware of the upcoming lead plaintiff deadline, which is crucial for those wishing to take on a more active role in the litigation. The Rosen Law Firm emphasizes the importance of acting promptly, as those seeking compensation may not be required to incur out-of-pocket expenses thanks to a contingency fee arrangement.

Steps to Join the Class Action

Interested investors can initiate their engagement with the class action lawsuit by visiting the Rosen Law Firm’s dedicated webpage or contacting Phillip Kim, Esq., for guidance. Staying informed is vital in such proceedings, as the lawsuit addresses claims regarding misleading information distributed by Unicycive about its business practices.

The Allegations Against Unicycive Therapeutics

According to the allegations outlined in the suit, during the class period, Unicycive’s representatives made statements that were either materially misleading or omitted critical information. Specifically, it is claimed that the company:
1. Did not properly inspect or audit the facilities of its third-party manufacturing vendor to ensure compliance with good manufacturing practices.
2. Failed to adequately disclose potential regulatory hurdles related to its product, oxylanthanum carbonate (OLC).
3. Misled investors about the operational status and future prospects of the company, which may lead to delayed FDA approval.

The failure to disclose these vital facts has resulted in significant damages for investors once the true state of affairs became public knowledge.

Why Choose Rosen Law Firm

Rosen Law distinguishes itself as a leader in handling securities class actions, requiring potential clients to carefully evaluate their legal representation options. Many law firms that issue notices often lack meaningful expertise in litigating these cases. Rosen Law has achieved notable settlements in the past, including the largest ever against a Chinese company, and maintains a high ranking for successful resolutions in securities class action cases. Their reputation is built on substantial recoveries for investors and quality legal guidance as shown by accolades and recognitions received by firm members.

Conclusion

For investors in Unicycive Therapeutics, now is a pivotal moment to assess whether to take part in this potential class action lawsuit. With the November deadline approaching, prompt action can significantly influence the ability to recover potential losses. For further information on how to proceed, interested parties are encouraged to reach out to the Rosen Law Firm, ensuring their rights are represented effectively.

For ongoing updates about this case, individuals can follow the firm's social media channels on LinkedIn, Twitter, and Facebook.

Disclaimer: Participation in the class action does not guarantee a favorable outcome, and it's essential to stay informed before making any decisions regarding legal representation.